Phase Ib/IIa clinical trial: Use of h-R3 monoclonal antibody and radiotherapy to treat patients with advanced epithelial head and neck tumors
Phase of Trial: Phase I/II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 31 Jul 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry record.
- 13 Feb 2013 Planned number of patients 12 added as reported by Cuban Clinical Trial Registry.
- 05 Nov 2010 New trial record.